

DESCRIPTION

Source	Human embryonic kidney cell, HEK293-derived human Activin A protein Gly311-Ser426 Accession # P08476.2
N-terminal Sequence Analysis	Gly311
Predicted Molecular Mass	13 kDa

SPECIFICATIONS


SDS-PAGE	14 kDa under reducing conditions, and 24 kDa under non-reducing conditions.
Activity	Measured by its ability to induce hemoglobin expression in K562 human chronic myelogenous leukemia cells. Schwall, R.H. <i>et al.</i> (1991) <i>Method Enzymol.</i> 198 :340. The ED ₅₀ for this effect is 0.200-1.60 ng/mL.
Endotoxin Level	<0.10 EU per 1 µg of the protein by the LAL method.
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Formulation	Lyophilized from a 0.2 µm filtered solution in Acetonitrile and TFA with Trehalose. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute 20 µg size at 100 µg/mL in sterile 4 mM HCl. Reconstitute all other sizes at 500 µg/mL in sterile 4 mM HCl.
Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 3 months, -20 to -70 °C under sterile conditions after reconstitution.


DATA

Bioactivity



Recombinant Human Activin A (HEK293 derived) Protein Bioactivity. Recombinant Human Activin A (HEK293 derived) induces hemoglobin expression in K562 human chronic myelogenous leukemia cells. The ED₅₀ for this effect is 0.200-1.60 ng/mL.

SDS-PAGE



Recombinant Human Activin A (HEK293 derived) Protein SDS-PAGE. 2 µg/lane of Recombinant Human Activin A (HEK293 derived) Protein (Catalog # 11344-AC) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 14 kDa and 24 kDa, respectively.

BACKGROUND

Activin and Inhibin are members of the TGF- β superfamily of cytokines and are involved in a wide range of biological processes including tissue morphogenesis and repair, fibrosis, inflammation, neural development, hematopoiesis, reproductive system function, and carcinogenesis (1-7). Activin and Inhibin are produced as precursor proteins. Their amino terminal propeptides are proteolytically cleaved and facilitate formation of disulfide-linked dimers of the bioactive proteins (8, 9). Activins are nonglycosylated homodimers or heterodimers of various β subunits (β A, β B, β C, and β E in mammals), while Inhibins are heterodimers of a unique α subunit and one of the β subunits. Activin A is a widely expressed homodimer of two β A chains. The β A subunit can also heterodimerize with a β B or β C subunit to form Activin AB and Activin AC, respectively (10). The 14 kDa mature human β A chain shares 100% amino acid sequence identity with bovine, feline, mouse, porcine, and rat β A. Activin A exerts its biological activities by binding to the type 2 serine/threonine kinase Activin RIIA which then noncovalently associates with the type 1 serine/threonine kinase Activin RIB/ALK-4 (7, 11). Signaling through this receptor complex leads to Smad activation and regulation of activin-responsive gene transcription (7, 11). The bioactivity of Activin A is regulated by a variety of mechanisms (11). BAMB1, Betaglycan, and Cripto are cell-associated molecules that function as decoy receptors or limit the ability of Activin A to induce receptor complex assembly (12-14). The intracellular formation of Activin A can be prevented by the incorporation of the β A subunit into Activin AC or Inhibin A (3, 10). And the bioavailability of Activin A is restricted by its incorporation into inactive complexes with α 2-Macroglobulin, Follistatin, and FLRG (15, 16). Activin A is involved in the differentiation of various cell and tissue types. The induction of definitive endoderm by Activin A is required in differentiation protocols of induced pluripotent stem cells (iPSCs) (17, 18). In vitro models of human gametogenesis use prolonged Activin A supplementation to human embryonic stem cells for differentiation into human primordial germ cell-like cells (19). Activin A can also be used to maintain cells in vitro, as is the case for iPSC-derived nephron cells that can then be used in disease modeling, drug screening and in regenerative medicine (20). Activin A is an important factor for tumor cells to evade the immune system as Activin A can act on surrounding immune cells to decrease their antitumor activity (21). Activin A also promotes migration and growth of tumors, making it a target for cancer therapies (22). Specifically, research has shown that interfering with Activin A activity can assist in overcoming CD8 T-cell exclusion and immunotherapy resistance (23). In bone marrow-derived stem cell transplants for treatment of diabetes, Activin A enhances migration and homing of stem cells towards pancreatic lineage (24).

References:

1. Kumanov, P. *et al.* (2005) *Reprod. Biomed. Online* **10**:786.
2. Maeshima, A. *et al.* (2008) *Endocr. J.* **55**:1.
3. Rodgarkia-Dara, C. *et al.* (2006) *Mutat. Res.* **613**:123.
4. Werner, S. and C. Alzheimer (2006) *Cytokine Growth Factor Rev.* **17**:157.
5. Xu, P. and A.K. Hall (2006) *Dev. Biol.* **299**:303.
6. Shav-Tal, Y. and D. Zipori (2002) *Stem Cells* **20**:493.
7. Chen, Y.G. *et al.* (2006) *Exp. Biol. Med.* **231**:534.
8. Gray, A.M. and A.J. Mason (1990) *Science* **247**:1328.
9. Mason, A.J. *et al.* (1996) *Mol. Endocrinol.* **10**:1055.
10. Thompson, T.B. *et al.* (2004) *Mol. Cell. Endocrinol.* **225**:9.
11. Harrison, C.A. *et al.* (2005) *Trends Endocrinol. Metab.* **16**:73.
12. Onichtchouk, D. *et al.* (1999) *Nature* **401**:480.
13. Gray, P.C. *et al.* (2002) *Mol. Cell. Endocrinol.* **188**:254.
14. Kelber, J.A. *et al.* (2008) *J. Biol. Chem.* **283**:4490.
15. Phillips, D.J. *et al.* (1997) *J. Endocrinol.* **155**:65.
16. Schneyer, A. *et al.* (2003) *Endocrinology* **144**:1671.
17. Ghorbani-Dalini, S. *et al.* (2020) *3 Biotech.* **10**:215.
18. Mennen, R. H. *et al.* (2022) *Reprod Toxicol.* **107**:44.
19. Mishra, S. *et al.* (2021) *Stem Cells.* **39**:551.
20. Tanigawa, S. *et al.* (2019) *Stem Cell Reports* **13**:322.
21. Cangkrama, M. *et al.* (2020) *Trends Mol. Med.* **26**:1107.
22. Ries, A. *et al.* (2020) *Expert Opin. Ther. Targets.* **24**:985.
23. Pinjusic, K. *et al.* (2022) *J. Immunother. Cancer.* **10**:e004533.
24. Dadheech, N. *et al.* (2020) *Stem Cell Res. Ther.* **11**:327.